6.59
1.23%
+0.08
Amneal Pharmaceuticals Inc stock is currently priced at $6.59, with a 24-hour trading volume of 890.89K.
It has seen a +1.23% increased in the last 24 hours and a +9.92% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.57 pivot point. If it approaches the $6.65 resistance level, significant changes may occur.
Previous Close:
$6.51
Open:
$6.49
24h Volume:
890.89K
Market Cap:
$2.03B
Revenue:
$2.50B
Net Income/Loss:
$-168.69M
P/E Ratio:
-329.50
EPS:
-0.02
Net Cash Flow:
$124.24M
1W Performance:
+7.68%
1M Performance:
+9.92%
6M Performance:
+62.32%
1Y Performance:
+226.24%
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Name
Amneal Pharmaceuticals Inc
Sector
Phone
908-947-3120
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
Mar-08-21 | Upgrade | Goldman | Sell → Buy |
Dec-14-20 | Upgrade | Barclays | Equal Weight → Overweight |
Dec-14-20 | Upgrade | Guggenheim | Neutral → Buy |
Jul-27-20 | Initiated | Goldman | Sell |
May-12-20 | Upgrade | Guggenheim | Sell → Neutral |
Dec-12-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-12-19 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jul-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Jul-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jul-08-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
Jun-11-19 | Initiated | Barclays | Equal Weight |
May-21-19 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
Mar-20-19 | Initiated | SunTrust | Buy |
Mar-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Dec-14-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-16-18 | Downgrade | SunTrust | Buy → Hold |
Aug-13-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Jul-23-18 | Initiated | Morgan Stanley | Overweight |
Jun-22-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Amneal Pharmaceuticals Inc Stock (AMRX) Latest News
Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts
Benzinga
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Zacks Investment Research
Amneal (AMRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?
Zacks Investment Research
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
Zacks Investment Research
Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data
Amneal Pharmaceuticals Inc (AMRX) Revenue 2024
AMRX reported a revenue (TTM) of $2.50 billion for the quarter ending March 31, 2024, a +9.82% rise year-over-year.
Amneal Pharmaceuticals Inc (AMRX) Net Income 2024
AMRX net income (TTM) was -$168.69 million for the quarter ending March 31, 2024, a -25.17% decrease year-over-year.
Amneal Pharmaceuticals Inc (AMRX) Cash Flow 2024
AMRX recorded a free cash flow (TTM) of $124.24 million for the quarter ending March 31, 2024, a +2,498% increase year-over-year.
Amneal Pharmaceuticals Inc (AMRX) Earnings per Share 2024
AMRX earnings per share (TTM) was -$0.74 for the quarter ending March 31, 2024, a +17.78% growth year-over-year.
About Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Cap:
|
Volume (24h):